Pro 2013-018 (Jianfeng Group's 2013 Corporate Bond Issuance Announcement)-1
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviations: Jianfeng Group Announcement Number: Pro 20 13 - 018
Zhejiang Jianfeng Group Co., Ltd. 20 13 Corporate Bonds (Phase I)
Issue Announcement
Sponsor (Lead Underwriter): zheshang Securities Co., Ltd.
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of announcement , and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important Note
, Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "Issuer", "Company" or "Jianfeng Group") Public Offering Corporate Bonds with Total Not Exceeding RMB .5 billion (Including .7 billion) (Below referred to as "this times bonds " ) has been approved by China securities regulatory Commission (hereinafter referred to as "China securities regulatory Commission ") securities regulatory license [2013]595 document .
This bond will be issued in installments, of which the first installment is to be issued at .7 billion yuan, that is, Zhejiang Jianfeng Group Co., Ltd. 2013 corporate bonds (the first installment) (hereinafter referred to as "current bonds").
2 , the face value of the current bond issue is RMB 30,000 yuan, each face value is RMB 100 yuan, totaling 300 , and the issue price is 100 yuan /.
3 , The current bond rating is AA + , and the main credit rating is AA ; Before the listing of this issue of bonds, the owner's equity (including minority shareholders' equity) in the consolidated statement of issuer as of 2012 # November was 164,643.81 .16 million yuan;# The asset-liability ratio of the 117 consolidated statement is 40.74 (the parent company's asset-liability ratio is 25.77 ) ; Before the current bond is listed, the average annual distributable profit realized by the issuer in the last three fiscal years is 18,836.85 .24 million yuan (taken from the average net profit attributable to the owner of the parent company in the consolidated statements of 2010 , 2011 and 2012 ) , is expected to be no less than 1.5 times of the one-year interest on this bond. The issuer's financial indicators prior to the Offering were in compliance with the relevant regulations.
5 , Current Bond by Tianjin Tianshili Group Co., Ltd. provides full unconditional and irrevocable joint and several liability guarantee .
6 , current bond is 5 -year fixed-rate bond (with 3 year-end issuer coupon rate increase option and investor resale option). The bonds bear interest on an annual basis at simple interest, without compound interest. The coupon rate shall be fixed for 3 160 years before the term of the bonds. If the issuer exercises the option to increase the coupon rate, the coupon rate for 2 years after the term of the bonds that have not been sold back shall be the coupon rate for 3 years before the term of the bonds 165 plus the increase basis point, and shall be fixed 2 years after the term of the bonds; if the issuer does not exercise the option to increase the coupon rate, the coupon rate of the portion of the bonds that have not been resold will remain unchanged at the original coupon rate for 2 years after their duration. The inquiry range of the coupon rate of the current bond is
4.60- 5.40 . The issuer and the sponsor (lead underwriter) will make an inquiry to offline institutional investors on 201 3 , , April 4 (T-1 ), and determine the final coupon rate of the bonds based on the inquiry . The issuer and the sponsor (lead underwriter) will announce the final coupon rate of the current bond on the 200 "shanghai securities news", "china securities journal" and the website of Shanghai Stock Exchange (www.sse.com.cn ) on 203 , , , , (T ). Please pay attention to it. 7 , This issue of bonds adopts a combination of online public offering to public investors and offline inquiry and placement to institutional investors
. Online subscription is completed in real time according to the principle of"time first " , and offline subscription is 215 by the issuer and the sponsor (lead underwriter) according to the inquiry. The specific issuance arrangements will be made in accordance with the relevant provisions of the Shanghai Stock Exchange . For the specific placement principles, please refer to "6 , Placing" in "4. Offline Issuance" of this announcement ". 8 , the number of bonds to be issued online and offline is 1,000 .26 million yuan and
29,000.28 million yuan respectively. The issuer and the sponsor (lead underwriter) will decide whether to start the callback mechanism according to the online issuance . If the online issuance quantity is fully subscribed, no callback will be made. If the online issuance quantity is insufficient, the remaining part will be transferred back to the offline issuance. If the offline subscription is insufficient, the undersubscribed 3 .3 billion yuan will be purchased by the lead underwriter by way of balance underwriting. This bond takes a one-way callback, not offline to online callback. 9 and Online Investors participate in the subscription through
Shanghai Stock ExchangeTrading System. The online distribution code is 751975 , which is referred to as "13 Peak 01 " . The minimum subscription unit for each securities account participating in this online issuance is 1 (10 , 1,000 yuan), and the number exceeding 1 must be an integer multiple of 1 . The number of online subscriptions is unlimited. After the issuance of this bond, the online issuance code 751975 will be converted to the listing code 122227 . 10 , Offline issuance is only for institutional investors. Institutional investors
participate in offline inquiry and subscription by submitting"Zhejiang Jianfeng Group Co., Ltd. 2013 Corporate Bonds (Phase I) Offline Interest Rate Inquiry and Application Form for Purchase" to the sponsor (lead underwriter). The minimum subscription quantity under the net is 1 (10 , 1,000 yuan), and the number exceeding 1 must be an integer multiple of 1 (I .e. 1 , 00 0 yuan). 11 . Investors shall not illegally use other people's accounts or funds to subscribe, nor shall they illegally finance or subscribe for other people. Investors who subscribe for and hold the bonds shall abide by the relevant laws and regulations and the relevant provisions of the China Securities Regulatory Commission, and bear the corresponding legal responsibilities.
12. Investors are requested to pay attention to the specific provisions of this Announcement on the issuance method, issuance object, issuance quantity, issuance time, subscription method, subscription procedure, subscription price and payment of subscription funds.
13 . The issuer will go through the relevant listing procedures as soon as possible after the issuance of the bonds, and the specific listing time will be announced separately.
14. This issue of bonds is issued to the whole market (including individual investors). After the issuance is completed, this issue of bonds is expected to be listed on the Shanghai Stock Exchange bidding trading system, block trading system and fixed income securities comprehensive electronic platform at the same time. The bond is eligible for repurchase and can enter the pledge library for repurchase transactions.
1 5 , this Announcement only explains matters related to the issuance of the bonds and does not constitute any investment advice for the bonds. For investors to learn more about the issuance of bonds in this issue, please carefully read the prospectus of
Zhejiang Jianfeng GroupCo., Ltd. public offering of corporate bonds (Phase I) . For information about this issue, investors can also go to the website of Exchange (http://www.sse. com. cn ) on . 1 6 . For other matters related to the issuance of this issue of bonds, the issuer and sponsor (lead underwriter) will make timely announcements on the website of shanghai securities news, china securities journal and Shanghai Exchange (
http://www.sse.com. cn ) as necessary. Please pay attention to investors. Interpretation Meaning
Unless otherwise stated, the following abbreviations have the following meanings in thisAnnouncement :
Issuer,
Jianfeng GroupRefers to |
Zhejiang Jianfeng Group Co., Ltd. |
Current Bond |
| Refers |
Zhejiang Jianfeng Group Co., Ltd. 201 3 Corporate Bonds | (Phase I)
This Issue |
| refers to the Issue of |
Bonds |
|
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05